LuciLaro — Larotrectinib 100 mg, 30 pcs, Lucius

LuciLaro — Larotrectinib Capsules 100 mg, 30 Capsules

Product code: 507

37995₴ 41437₴ -8% On order · from 10 days

Analogues

Laronib 100 LuciLaro
1
Active ingredient
Dosage
100 mg
Dosage form Capsules
Capsules per pack 30

LuciLaro is a highly selective, innovative targeted antineoplastic agent belonging to the tropomyosin receptor kinase (TRK) inhibitor class, indicated for the treatment of a broad spectrum of solid tumors harboring NTRK gene fusions. The active pharmaceutical ingredient is larotrectinib at a strength of 100 mg supplied as hard gelatin capsules (Larotrectinib Capsules 100 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Larotrectinib is a first-in-class, potent, oral, selective inhibitor of TRK proteins (TRKA, TRKB, and TRKC). NTRK gene fusions result in aberrant chimeric TRK proteins that drive continuous tumor growth and proliferation regardless of the primary tumor's anatomical location (so-called tumor-agnostic therapy). Larotrectinib demonstrates high efficacy across diverse cancer types (including soft tissue sarcomas, salivary gland cancer, infantile fibrosarcoma, thyroid cancer, lung cancer, colon cancer, etc.) harboring NTRK fusions in both adult and pediatric patients.

Supplied in a package containing 30 capsules of 100 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciLaro 100 mg:

  • ✅ Next-Generation TRK Inhibitor: Highly selective suppression of chimeric TRKA/B/C proteins.
  • ✅ Tumor-Agnostic Therapy: Efficacy in any solid tumor harboring NTRK gene fusions.
  • ✅ High Response Rates: Rapid and profound tumor shrinkage with minimal systemic toxicity.
  • ✅ Convenient Capsule Form: Oral administration twice daily regardless of food intake.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Vitrakvi).

LuciLaro is supplied as hard gelatin capsules for oral administration.

Qualitative and Quantitative Composition per Capsule:

  • Active Ingredient: Larotrectinib (as larotrectinib sulfate) — 100 mg.
  • Excipients: Microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate. Capsule shell: gelatin, titanium dioxide, colorants.

Packaging and Presentation: Hard capsules, 100 mg strength. Each package contains 30 capsules along with prescribing information. Labeled with LuciLaro (Larotrectinib Capsules 100 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Larotrectinib is a potent, oral, selective, reversible inhibitor of tropomyosin receptor kinases (TRKs), encompassing TRKA, TRKB, and TRKC. When NTRK genes (NTRK1, NTRK2, NTRK3) fuse with unrelated partner genes, abnormal fusion proteins are produced, causing constitutive kinase activation and uncontrolled tumor cell proliferation. Larotrectinib competitively binds to the ATP-binding pocket of TRK kinases, blocking their activity, leading to growth arrest and apoptosis of tumor cells.

Pharmacokinetics:

  • Absorption: Following oral administration, larotrectinib is rapidly absorbed; peak plasma concentration (Tmax) is achieved within approximately 1 hour. Absolute bioavailability is approximately 34%. Food intake has no clinically significant effect on overall exposure.
  • Distribution: Human plasma protein binding is approximately 70%. High volume of distribution ensures tissue penetration, including the central nervous system.
  • Metabolism: Extensively metabolized in the liver, primarily via CYP3A4 enzyme of the cytochrome P450 system.
  • Elimination: Excreted predominantly via feces (approx. 58% as metabolites) and renally (approx. 39%). Terminal elimination half-life (T1/2) averages approximately 2.8 hours.

LuciLaro is indicated in adult and pediatric patients for:

  • Solid Tumors with NTRK Gene Fusions: Treatment of adult and pediatric patients with locally advanced or metastatic solid tumors that harbor an NTRK gene fusion without a known acquired resistance mutation, who have progressed following prior treatment, or who have no satisfactory alternative treatment options.

LuciLaro is administered orally twice daily every day (morning and evening) approximately every 12 hours until disease progression or unacceptable toxicity occurs.

Dosing Regimen for Adults:
The recommended standard adult dose is 100 mg (one 100 mg capsule) twice daily (total daily dose of 200 mg).

Administration Guidelines:
Capsules should be swallowed whole with a glass of water; do not break, crush, open, or chew. Can be taken with or without food. If a dose is missed or vomiting occurs after ingestion, take the next dose at the scheduled time (do not double doses).

Administration of LuciLaro is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to larotrectinib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction (requiring dosage adjustment or discontinuation).

Larotrectinib is metabolized in the liver primarily via CYP3A4:

  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): May significantly increase larotrectinib plasma concentrations and toxicity risks (avoid concurrent use or reduce dose).
  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease larotrectinib blood concentrations and reduce efficacy (avoid concurrent use).
  • CYP3A4 Substrates: Larotrectinib may exert mild effects on certain substrates.

Pregnancy:
LuciLaro is contraindicated during pregnancy. Based on its mechanism of action, larotrectinib may cause fetal harm and embryotoxicity. Females of reproductive potential and male partners must utilize effective reliable contraception during treatment and for at least 1 month following the final dose.

Lactation:
Excretion of larotrectinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Gastrointestinal Tract: Nausea, diarrhea, constipation, vomiting.
  • General Disorders: Fatigue, asthenia, dizziness, peripheral edema, weight increase.
  • Nervous System: Headache, paresthesia, cognitive impairment.
  • Laboratory Abnormalities: Elevations in liver transaminases (ALT, AST), increased blood alkaline phosphatase, anemia, neutropenia.

Symptoms:
Specific acute overdose symptoms of larotrectinib are unestablished. Anticipated manifestations include exacerbated neurological adverse effects (dizziness, fatigue) and gastrointestinal disturbances.

Treatment:
No specific antidote exists. In case of overdose, discontinue treatment and initiate supportive and symptomatic care under medical supervision.

Storage Requirements for LuciLaro 100 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciLaro 100 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Larotrectinib Capsules 100 mg, and 30 Capsules count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 15.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00